Literature DB >> 17089378

The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.

Rebecca E Saunders1, Cynthia Abarrategui-Garrido, Véronique Frémeaux-Bacchi, Elena Goicoechea de Jorge, Timothy H J Goodship, Margarita López Trascasa, Marina Noris, Isabel Maria Ponce Castro, Giuseppe Remuzzi, Santiago Rodríguez de Córdoba, Pilar Sánchez-Corral, Christine Skerka, Peter F Zipfel, Stephen J Perkins.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a disease of hemolytic anemia, thrombocytopenia, and renal failure associated with defective alternative pathway (AP) complement control. Previously, we presented a database (www.FH-HUS.org) focusing on aHUS mutations in the Factor H gene (CFH). Here, new aHUS mutations are reported for the complement regulatory proteins Factor H (FH), Factor I (FI), and membrane cofactor protein (MCP). Additional mutations or polymorphisms within CFH have been associated with membranoproliferative glomerulonephritis (MPGN) and age-related macular degeneration (AMD). Accordingly, the database now includes substitutions that predispose to aHUS, MPGN, and AMD. For this, structural models for the domains in MCP and FI were developed using homology modeling. With this new database, patients with mutations in more than one gene can be displayed and interpreted in a coherent manner. The database also includes SNP polymorphisms in CFH, MCP, and IF. There are now a total of 167 genetic alterations, including 100 in CFH, 43 in MCP, and 24 in IF. The mutations characterize clinical outcomes that vary from several AMD-associated polymorphisms to those associated with aHUS, MPGN, or FI deficiency. A consensus short complement regulator (SCR) domain structure facilitated the interpretations of aHUS mutations. Specific locations within this consensus domain often correlate with the occurrence of clinical phenotypes. The AMD Tyr402His polymorphism is structurally located at a hotspot for several aHUS mutations. The database emphasizes the causative role of the alternative pathway of complement in disease and provides a repository of knowledge to assist future diagnosis and novel therapeutic approaches. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17089378     DOI: 10.1002/humu.20435

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  50 in total

Review 1.  Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane.

Authors:  Peter F Zipfel; Richard J H Smith; Christine Skerka
Journal:  Nephrol Dial Transplant       Date:  2008-12-04       Impact factor: 5.992

2.  Constrained solution scattering modelling of human antibodies and complement proteins reveals novel biological insights.

Authors:  Stephen J Perkins; Azubuike I Okemefuna; Ruodan Nan; Keying Li; Alexandra Bonner
Journal:  J R Soc Interface       Date:  2009-07-15       Impact factor: 4.118

Review 3.  Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?

Authors:  Peter F Zipfel; Gunter Wolf; Ulrike John; Karim Kentouche; Christine Skerka
Journal:  Pediatr Nephrol       Date:  2011-06-14       Impact factor: 3.714

Review 4.  Cardiovascular complications in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

5.  Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP.

Authors:  Dana Provaznikova; Simon Rittich; Michal Malina; Tomas Seeman; Iuri Marinov; Magdalena Riedl; Ingrid Hrachovinova
Journal:  Pediatr Nephrol       Date:  2011-06-27       Impact factor: 3.714

6.  A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome.

Authors:  Michinori Funato; Osamu Uemura; Katsumi Ushijima; Hidenori Ohnishi; Kenji Orii; Zenichiro Kato; Satoshi Yamakawa; Takuhito Nagai; Osamu Ohara; Hideo Kaneko; Naomi Kondo
Journal:  J Clin Immunol       Date:  2014-06-08       Impact factor: 8.317

7.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

8.  Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.

Authors:  Jon Jin Kim; Tim H J Goodship; Jane Tizard; Carol Inward
Journal:  Pediatr Nephrol       Date:  2011-06-30       Impact factor: 3.714

Review 9.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

Review 10.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.